Sudden death in heart failure associated with reduced left ventricular function: Substrates, mechanisms, and evidence-based management, part II

PACE - Pacing and Clinical Electrophysiology

Volumn 24, Issue 6, 2001, Pages 1002-1022

  Sweeney, Michael O ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; INOTROPIC AGENT; METOPROLOL; PROPAFENONE;

CLINICAL TRIAL; DEFIBRILLATOR; DISEASE ASSOCIATION; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE TACHYCARDIA; HUMAN; REVIEW; SUDDEN DEATH; TREATMENT OUTCOME;

EID: 0034926447     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9592.2001.01002.x     Document Type: Review

References (101)

1. Effect of captopril on mortality and morbidity among patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement trial
2. Overview of randomised trials of angiotensin-converting enzyme inhibitors on mortality and morbidity among patients with heart failure
3. Enalapril decreases prevalence of ventricular tachycardia among patients with chronic congestive heart failure
4. Lack of long-term ventricular arrhythmia reduction by enalapril in heart failure patients: A double-blind, parallel placebo controlled trial
5. Morphometry of human coronary capillaries during normal growth and the effect of age in left ventricular pressure-overload hypertrophy
6. Effect of vasodilator drugs on coronary occlusion and reperfusion arrhythmias in anesthetized dogs
7. Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: A comparison of captopril, enalapril and HOE 498
8. Does captopril attenuate reperfusion-induced myocardial dysfunction by scavenging free radicals?
9. "Escape" of aldosterone production among patients with left vantricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy
10. The effect of spironolactone on morbidity and mortality among patients with severe heart failure
11. Instantaneous cardiac death in the posthospital period after myocardial infarction
12. The effect of digoxin on mortality and morbidity in patients with heart failure
13. Effect of oral milrinone on mortality in severe chronic heart failure
14. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure: Results of multicenter trial
15. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial
16. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure
17. Inotropic therapy for heart failure
18. Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
19. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction
20. The Cardiac Arrhythmia Suppression Trial: Casting suppression in a different light
21. Association between ease of suppression of ventricular arrhythmia and survival
22. th Annual Scientific Sessions of the American College of Cardiology
23. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation
24. Quinidine: Worse than adverse?
25. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: An overview of results from randomized controlled trials
26. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction
27. Mortality in the Survival with Oral D-Sotalol (SWORD) Trial: Why did patients die?
28. Electrophysiologic and hemodynamic effects of dofetilide among patients with depressed left ventricular function: A randomized, double-blind, placebo-controlled study
29. Dofetilide among patients with congestive heart failure and left ventricular dysfunction
30. Plasma norepinephrine as a guide to prognosis among patients with chronic heart failure
31. Effect of propanolol after acute MI among patients with congestive heart failure
32. Beta-blockers after MI: Influence of first-year clinical course on long-term effectiveness
33. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy
34. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade
35. Medical therapy can improve the biologic properties of the chronically failing heart: A new era in the treatment of heart failure
36. The effect of carvedilol on morbidity and mortality among patients with chronic heart failure
37. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF)
38. The cardiac insufficiency bisoprolol study II: A randomized trial
39. The Sicilian Gambit: A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms
40. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle
41. Amiodarone: Pharmacology, clinical actions, and relationships between them
42. Kinetics of use-dependent ventricular conduction slowing by antiarrhythmic drugs in humans
43. Frequency-dependent effects of amiodarone on atrioventricular nodal function and slow-channel action potentials. Evidence for calcium channel-blocking activity
44. Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoreceptors
45. Magnitude and time course of beta-adrenergic antagonism during oral amiodarone therapy
46. Amiodarone interaction with beta-blockers: Analysis of merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases
47. Heart rate is a marker of amiodarone mortality reduction in severe heart failure
48. Randomized trial of low-dose amiodarone in severe congestive heart failure
49. Randomized trial of outcome after myocardial infarction among patients with frequent or repetitive ventricular premature depolarizations: CAMIAT
50. Randomized trial of effect of amiodarone on mortality among patients with left ventricular dysfunction after recent myocardial infarction: EMIAT
51. Effects of chronic amiodarone therapy on ventricular tachycardia induced by programmed ventricular stimulation
52. Amiodarone: Correlation of early and late electrophysiologic studies with outcome
53. Use-dependent prolongation of ventricular tachycardia cycle length by type I antiarrhythmic drugs in humans
54. Hemodynamic effects of intravenous amiodarone
55. Intravenous amiodarone: Pharmacology, pharmacokinetics, and clinical use
56. Prospective, double-blind, placebo-controlled trials of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy
57. Amiodarone
58. Adverse effects of low dose amiodarone: A meta-analysis
59. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia
60. Evidence-based analysis of amiodarone efficacy and safety
61. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS)
62. Effect of amiodarone on mortality after myocardial infarction: A double-blind, placebo-controlled, pilot study
63. Beneficial effect of amiodarone on cardiac mortality among patients with asymptomatic complex ventricular arrhythmias after acute myocardial infarction and preserved but not impaired left ventricular function
64. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomized trials
65. Improving survival for patients with advanced heart failure: A study of 737 consecutive patients
66. The CASCADE Study: Randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle
67. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias
68. Causes of death in the antiarrhythmics versus implantable defibrillators (AVID) trial
69. Canadian implantable defibrillator study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone
70. Sudden cardiac death and national health
71. Unsustained ventricular tachycardia-to treat or not to treat
72. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery
73. CABG surgery unlinked the arrhythmic substrate from arrhythmic outcomes in the CABG-Patch Trial
74. Side effects from amiodarone
75. Determinants of predicted efficacy of antiarrhythmic drugs in the electrophysiologic study versus electrocardiographic monitoring trial
76. Inverse relationship between baseline left ventricular ejection fraction and the outcome of antiarrhythmic drug therapy
77. Out-of-hospital cardiac arrest: Use of electrophysiologic testing in the prediction of long-term outcome
78. Influence of implantable cardioverter-defibrillators on the long-term prognosis of survivors of out-of-hospital cardiac arrest
79. Role of invasive electrophysiological testing in the evaluation and treatment of patients at high risk for sudden cardiac death
80. Determinants of survival in patients with ventricular tachyarrhythmias
81. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmia drugs among patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias
82. The low arrhythmic frequency sextile: A subgroup that doesn't need an implanted defibrillator
83. Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: The Canadian Implantable Defibrillator Study
84. Implantable cardioverter defibrillator therapy: The sickest patients benefit the most
85. Primary prevention of sudden cardiac death in heart failure: Will the result be shocking?
86. The implantable defibrillator: An electronic bridge to cardiac transplantation
87. AICD as a bridge to transplant
88. Automatic internal cardioverter defibrillator: A bridge to heart transplantation
89. Influence of the implantable cardioverter-defibrillator on sudden death and total mortality in patients evaluated for cardiac transplantation
90. Sudden death in patients with implantable cardioverter defibrillators: The importance of cardiac annihilation
91. Mortality in octagenerians after implantation of implantable cardioverter-defibrillators: When is too old?
92. The cost-effectiveness of automatic implantable cardioverter-defibrillators: Results from MADIT
93. Cost-effectiveness of the implantable cardioverter defibrillator: Results of the Canadian Implantable Defibrillator Study (CIDS)
94. Longevity of newer generation implantable cardioverter defibrillators
95. International survery of prophylactic defibrillator implantation
96. Cardiac arrest treated with a new automatic external defibrillator by out-of-hospital first responders
97. Rapid defibrillation by nontraditional responders: The casino project
98. High discharge survival rate after out-of-hospital ventricular fibrillation with rapid defibrillation by police and paramedics
99. Encouraging early defibrillation: The American Heart Association and automatic external defibrillators
100. Defibrillation aboard a commercial aircraft
101. Comparison of naïve sixth-grade children with trained professionals in the use of an automated external defibrillator